Virological fitness of HIV in patients with resistance to enfuvirtide.
Resistance to the HIV fusion inhibitor enfuvirtide is associated with mutations in the first heptad repeat region of gp41, but little is known of their impact on replicative fitness in vivo. We followed seven patients undergoing salvage therapy that included enfuvirtide in order to document the temporal generation of genotypic and phenotypic resistance in parallel with replicative fitness. Resistance to enfuvirtide was not associated with decreased replicative fitness of HIV strains infecting these patients.
Chibo
Doris
D
Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia.
Roth
Norman
N
Roulet
Vanessa
V
Skrabal
Katharina
K
Gooey
Megan
M
Carolan
Louise
L
Nicholls
Jodie
J
Papadakis
Anastasia
A
Birch
Chris
C
D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D018791:CD4 Lymphocyte Count; D024882:Drug Resistance, Viral / Q000235:genetics; D000077560:Enfuvirtide; D005838:Genotype; D006678:HIV / Q000187:drug effects / Q000235:genetics*; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D009154:Mutation; D010446:Peptide Fragments / Q000627:therapeutic use*; D010641:Phenotype; D017211:Treatment Failure; D019562:Viral Load; D014779:Virus Replication / Q000235:genetics
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide